Sacubitril/valsartan has been shown to reduce cardiovascular mortality and hospitalizations in patients with HFrEF when compared to enalapril. There are also some evidences of its potential antiarrhythmic effects. We present a report where we found a relation between reverse ventricular remodeling and arrhythmic reduction in a patient treated with sacubitril/valsartan.
Corrado E., Saladino A., Morgante G., Mignano A., Nugara C., Novo G., et al. (2020). Reverse remodeling and arrhythmic burden reduction in a patient with an implantable cardioverter defibrillator treated with sacubitril/valsartan: Case report. CLINICAL CASE REPORTS, 8(8), 1349-1352 [10.1002/ccr3.2655].
Reverse remodeling and arrhythmic burden reduction in a patient with an implantable cardioverter defibrillator treated with sacubitril/valsartan: Case report
Corrado E.;Nugara C.;Novo G.;Coppola G.
2020-01-01
Abstract
Sacubitril/valsartan has been shown to reduce cardiovascular mortality and hospitalizations in patients with HFrEF when compared to enalapril. There are also some evidences of its potential antiarrhythmic effects. We present a report where we found a relation between reverse ventricular remodeling and arrhythmic reduction in a patient treated with sacubitril/valsartan.
| File | Dimensione | Formato | |
|---|---|---|---|
|
ccr3.2655 (1).pdf
accesso aperto
Dimensione
453.96 kB
Formato
Adobe PDF
|
453.96 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
